MET and non-small cell lung carcinoma: This limit will acquire greater importance in the near future, because it is expected to equally hinder feasibility of all next-line targeted therapies for ALK+ NSCLC, for example also newly-developed fourth-generation ALK inhibitors directed against compound ALK mutations (30), or other drugs targeting other actionable resistance mechanisms, such as acquired MET amplifications or KRAS mutations (9).